Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 7/20 | 0.38 |
| ▸ | UCHL1 | P09936 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.34 |
| ▸ | CDK2 | P24941 | 3/20 | 0.34 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | GCK | P35557 | 1/20 | 0.32 |
| ▸ | OGA | O60502 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17632008 | 0.84 | UCHL1 (0.44) | USP30UCHL1SMN1; SMN2CCNE1CDK2 | |
| SCHEMBL17644063 | 0.84 | UCHL1 (0.44) | USP30UCHL1SMN1; SMN2CCNE1CDK2 | |
| SCHEMBL22494637 | 0.75 | SMN1; SMN2 (0.42) | USP30UCHL1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL22494638 | 0.75 | SMN1; SMN2 (0.42) | USP30UCHL1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL23452840 | 0.74 | UCHL1 (0.40) | UCHL1SMN1; SMN2RAB9ACCNE1CDK2 | |
| SCHEMBL17643828 | 0.74 | UCHL1 (0.62) | USP30UCHL1 | |
| SCHEMBL17631690 | 0.74 | UCHL1 (0.62) | USP30UCHL1 | |
| SCHEMBL17631844 | 0.73 | USP30 (0.60) | USP30UCHL1 | |
| SCHEMBL17643702 | 0.73 | USP30 (0.60) | USP30UCHL1 | |
| SCHEMBL23452856 | 0.73 | USP30 (0.60) | USP30UCHL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180162852-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LIMITED | 2018-06-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162852-A1 | NOVEL COMPOUNDS | UCHL1, UCHL3, UCHL5 | USP30 19/4885UCHL1 1/4885SMN1; SMN2 3600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.